Received over 11,000 five star verified reviews, and counting

Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)

This study has been completed.

Information provided by (Responsible Party):
Clinuvel Pharmaceuticals Limited Identifier:
First received: May 10, 2007
Last updated: October 4, 2011
Last verified: October 2011

The purpose of this study is to determine whether the Melanotan 2 (afamelanotide CUV1647) formulation is effective in preventing PLE episodes or reducing the severity of PLE symptoms in patients with a well documented history of the disease. The study also aims to determine whether treatment with afamelanotide (CUV1647) can reduce the use of rescue medication in this group.


Condition Intervention Phase
Polymorphic Light Eruption (PLE) Drug: Afamelanotide (CUV1647) Phase 3


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Phase III, Randomised, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of CUV1647 in Patients Suffering From Polymorphic Light Eruption (PLE).

Resource links provided by NLM:


MedlinePlus related topics:

U.S. FDA Resources


Further study details as provided by Clinuvel Pharmaceuticals Limited:


Primary Outcome Measures:

  • To evaluate whether afamelanotide (CUV1647) prevents episodes or reduces the severity of PLE symptoms in patients with a well documented history of PLE [ Time Frame: 18 months ] [ Designated as safety issue: No ]


Secondary Outcome Measures:

  • To evaluate the safety and tolerability of afamelanotide (CUV1647) in this specific clinical setting [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To evaluate the effect of afamelanotide (CUV1647) on melanin density levels as measured by skin reflectance [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To evaluate whether afamelanotide (CUV1647) has a beneficial effect on the quality of life of patients with a documented history of PLE [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To determine if there are other factors that may influence the severity of PLE symptoms eg. sun exposure and use of sun protection methods [ Time Frame: 18 months ] [ Designated as safety issue: No ]


Enrollment: 18
Study Start Date: May 2007
Study Completion Date: September 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)

Intervention Details:





16mg implant


Detailed Description:

Polymorphic Light Eruption (PLE) is a prevalent photosensitivity disorder, occurring in up to 20% of the European and US populations and up to 5% of the Australian population. The disease is characterised by a rash that is intensely itchy with blisters, bumps and patches presenting on areas of the skin that have been exposed to the sun. There is a lack of effective treatment available for the condition but the most common available forms of therapy include sun avoidance and the use of the use of steroids and/or phototherapy.


Ages Eligible for Study: 18 Years to 70 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Sampling Method: Non-Probability Sample
Study Population

Patients with moderate/severe polymorphic light eruption (PLE)


Inclusion Criteria:

  • Aged 18 – 70 years at inclusion.
  • Well documented history of moderate/severe PLE as diagnosed/confirmed by a photodermatologist or photobiologist. Newly diagnosed patients with moderate/severe PLE can be included if numbers of established patients are limited provided their diagnosis is confirmed by a photodermatologist or photobiologist.
  • Recurrent episodes that occur at least once a year, developing in own country (to exclude patients affected only when traveling to sunnier climates).
  • Have given written informed consent to participate in the study.

Exclusion Criteria:

  • Personal history of melanoma, lentigo maligna or multiple (3 or more) dysplastic nevi.
  • Current Bowen’s Disease, basal cell carcinoma, squamous cell carcinoma or other malignant skin lesions.
  • Documented history of other photosensitive conditions.
  • Female who is pregnant (confirmed by positive serum β-HCG pregnancy test prior to baseline) or lactating.
  • Females of child-bearing potential that are not using adequate contraceptive measures.

Contacts and Locations

Please refer to this study by its identifier: NCT00472901

St Vincents Hospital
Melbourne, Australia
Medical University of Vienna
Vienna, Austria, A1090
United Kingdom
Hope Hospital
Manchester, United Kingdom

Sponsors and Collaborators
Clinuvel Pharmaceuticals Limited

Principal Investigator: Lesley Rhodes, MD Hope Hospital, Manchester, United Kingdom
Principal Investigator: Herbert Hoenigsmann, MD Medical University of Vienna
Principal Investigator: Chris Baker, MD St Vincent’s Hospital, Melbourne, Australia

More Information

No publications provided

Responsible Party: Clinuvel Pharmaceuticals Limited Identifier: NCT00472901
History of Changes
Other Study ID Numbers: CUV015
Study First Received: May 10, 2007
Last Updated: October 4, 2011
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Australia: Department of Health and Ageing Therapeutic Goods Administration
Austria: Austrian Federal Agency for Safety in Healthcare AGES/PharmMed

Keywords provided by Clinuvel Pharmaceuticals Limited:

Polymorphic Light Eruption (PLE)AfamelanotideCUV1647photoprotectionsun poisoning

Additional relevant MeSH terms:

ExanthemaDermatitis, ContactSkin DiseasesDermatitisSkin Diseases, Eczematous processed this record on April 03, 2014